Prostate cancerOH, William K.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, 238 p.Serial Issue

Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints : The high-risk prostate cancer patientOH, William K.Urologic oncology. 2003, Vol 21, Num 3, pp 229-234, issn 1078-1439, 6 p.Article

Bone-directed treatments for prostate cancerSAAD, Fred.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, x-xi, 947-963 [19 p.]Article

Chemotherapy for high-risk localized prostate cancerNAKABAYASHI, Mari; OH, William K.BJU international (Papier). 2006, Vol 97, Num 4, pp 679-683, issn 1464-4096, 5 p.Article

Chemotherapy for advanced prostate cancer : Docetaxel and beyondDREICER, Robert.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, x, 935-946 [13 p.]Article

Androgen deprivation therapy : Monitoring and managing the complicationsHIGANO, Celestia.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, ix-x, 909-923 [17 p.]Article

Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancerNAKABAYASHI, Mari; BARTLETT, Richard A; OH, William K et al.Journal of clinical oncology. 2006, Vol 24, Num 18, pp 2958-2959, issn 0732-183X, 2 p.Article

Secondary hormonal manipulations in prostate cancerRYAN, Charles J.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, x, 925-934 [11 p.]Article

New clinical imaging modalities in prostate cancerROSS, Robert; HARISINGHANI, Mukesh.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, vii-viii, 811-830 [22 p.]Article

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?OH, William K; TAY, Miah-Hiang; JIAOTI HUANG et al.Cancer. 2007, Vol 109, Num 3, pp 477-486, issn 0008-543X, 10 p.Article

Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen resultsLEIBOWITZ, Stacey B; OH, William K.The Journal of urology. 2003, Vol 170, Num 4, issn 0022-5347, p. 1305, 1Article

Higher Prostate-specific Antigen Levels Predict Improved Survival in Patients With Hormone-refractory Prostate Cancer Who Have Skeletal Metastases and Normal Serum Alkaline PhosphataseWANLING XIE; NAKABAYASHI, Mari; REGAN, Meredith M et al.Cancer. 2007, Vol 110, Num 12, pp 2709-2715, issn 0008-543X, 7 p.Article

New insights into prostate cancer biologyBALAKUMARAN, Bala S; FEBBO, Phillip G.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, vii, 773-796 [25 p.]Article

Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapyDASKIVICH, Timothy J; REGAN, Meredith M; OH, William K et al.Urology (Ridgewood, NJ). 2007, Vol 70, Num 3, pp 527-531, issn 0090-4295, 5 p.Article

New targets in the management of prostate cancerHEATH, Elisabeth I; CARDUCCI, Michael A.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, xi, 985-999 [16 p.]Article

Progressive sclerosis of isolated foot metastasis of prostate cancerOH, William K; LODA, Massimo; KANTOFF, Philip W et al.The Journal of urology. 2002, Vol 167, Num 3, issn 0022-5347, p. 1392Article

Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma report of four casesOH, William K; GEORGE, Daniel J; KANTOFF, Philip W et al.Cancer. 2002, Vol 94, Num 3, pp 686-689, issn 0008-543XArticle

PC-SPES and prostate cancerOH, William K; SMALL, Eric J.Urologic clinics of North America. 2002, Vol 29, Num 1, issn 0094-0143, viii, 59-66 [8 p.]Article

Complementary and alternative therapies in prostate cancerOH, William K; SMALL, Eric J.Seminars in oncology. 2002, Vol 29, Num 6, pp 575-584, issn 0093-7754, 10 p.Article

Prostate specific antigen doubling time calculation : Not as easy as 1, 2, 4DASKIVICH, Timothy J; REGAN, Meredith M; OH, William K et al.The Journal of urology. 2006, Vol 176, Num 5, pp 1927-1937, issn 0022-5347, 11 p.Article

Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate CancerTSAO, Che-Kai; GALSKY, Matthew D; OH, William K et al.European urology. 2014, Vol 66, Num 2, pp 184-185, issn 0302-2838, 2 p.Article

Update on radiation therapy in prostate cancerLEE, Andrew K; FRANK, Steven J.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, viii-ix, 24857-878Article

Management of the patient with a rising PSA aloneMOUL, Judd W; WARD, John F.Hematology/oncology clinics of North America. 2006, Vol 20, Num 4, issn 0889-8588, ix, 897-908 [13 p.]Article

Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-AnalysisSONIA SENG; ZIYUE LIU; GALSKY, Matthew D et al.Journal of clinical oncology. 2012, Vol 30, Num 35, pp 4416-4426, issn 0732-183X, 11 p.Article

Elevated Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Predict Decreased Survival in Castration-Resistant Prostate Cancer PatientsOH, William K; VARGAS, Roberto; KANTOFF, Philip W et al.Cancer. 2011, Vol 117, Num 3, pp 517-525, issn 0008-543X, 9 p.Article